ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Evotec spin-off Breakpoint launches to develop anticancer drugs

by Ryan Cross
July 12, 2019 | APPEARED IN VOLUME 97, ISSUE 28

 

A Hamburg, Germany–based start-up called Breakpoint Therapeutics has launched with $33.6 million to develop drugs that inhibit DNA-repair mechanisms. Breakpoint is a spin-off from the German contract research firm Evotec, which, along with Medicxi and Taiho Ventures, is funding the company. Breakpoint hopes that its compounds will deal a fatal blow to drug-resistant cancer cells. It wants to have a drug candidate ready for testing in 2022.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment